Skip to main content
METex14, Meet Mary

"I found a treatment that's a match for me."

The first treatment specifically for metastatic non-small cell lung cancer (mNSCLC) with an abnormality in the MET gene called MET exon 14 skipping (METex14).

TESTING AND DIAGNOSIS

Biomarker testing matters

Comprehensive testing may identify MET exon 14 skipping status and could help inform treatment decisions.

HOW TABRECTA MAY HELP

Treatment with TABRECTA

Discover proven results from the clinical trial.